- Perrigo Company plc recently reported full-year 2025 results showing sales of US$4,253.1 million, with net loss widening to US$1,425.4 million, and also issued 2026 guidance pointing to a further 1.5%–5.5% decline in total net sales versus the prior year.
- Despite this much larger loss, including a particularly weak fourth quarter, the board maintained its quarterly dividend at US$0.29 per share, signaling a continued cash return to shareholders.
- We’ll now examine how Perrigo’s sharply higher 2025 net loss and weaker 2026 sales outlook may reshape the company’s longer-term investment narrative.
Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
Perrigo Investment Narrative Recap
To own Perrigo today, you need to believe its store-brand self-care and OTC model can still convert consumer cost-consciousness into steady, profitable demand, despite softer categories and intense competition. The sharp swing to a 2025 net loss of US$1,425.4 million and a 2026 sales outlook of a further 1.5% to 5.5% decline heighten near term concern around profitability and cash generation, making execution on cost savings and category stabilization the key catalyst, and sustained losses the central risk.
Against that backdrop, the board’s decision on 19 February 2026 to affirm a US$0.29 quarterly dividend stands out. Keeping the payout intact, even after a particularly weak fourth quarter in which the company lost US$1,418.1 million on US$1,109.6 million of sales, ties the investment case more closely to Perrigo’s ability to fund shareholder returns from future cash flows, at a time when earnings are firmly in the red and 2026 guidance points to declining revenue.
Yet behind the appeal of a maintained dividend, investors should be aware of the growing tension between large net losses and ongoing cash returns...
Read the full narrative on Perrigo (it's free!)
Perrigo's narrative projects $4.6 billion revenue and $183.6 million earnings by 2028. This requires 1.7% yearly revenue growth and a $243.1 million earnings increase from $-59.5 million today.
Uncover how Perrigo's forecasts yield a $21.00 fair value, a 84% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already cautious, assuming only about 1.1% annual revenue growth and earnings of roughly US$200 million by 2028, so after this guidance cut you should expect that even more pessimistic views on demand softness and margin pressure might emerge, and it is worth seeing how your own expectations compare.
Explore 4 other fair value estimates on Perrigo - why the stock might be worth just $21.00!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Perrigo research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Perrigo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Perrigo's overall financial health at a glance.
Ready For A Different Approach?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
- Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com